Calder’s RSV program has achieved pre-clinical animal proof of principle and has begun scaled clinical manufacturing process development. Our universal influenza program has solved all major engineering hurdles and the vaccine will be ready for preclinical animal testing in Q2 of 2021, and our pan-coronavirus discovery program is initiated.